Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
A
BuyPremium GrowerFLAGAgilent Technologies, Inc. · Healthcare · United States · $43.4B · Avg Vol: $296M/d
Insufficient evidence for a screen-pass. Agilent Technologies, Inc.: fails the quant gate on value (Q69/V33/M68; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.
COMPANY DESCRIPTION
Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, providing analytical instruments, software, services, and consumables. Its competitive advantage stems from its comprehensive portfolio of high-precision scientific tools and strong R&D capabilities that serve critical research and quality control functions. Agilent operates as a key enabler for advancements in pharmaceuticals, food safety, environmental analysis, and diagnostics worldwide.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.8B | 6.8B | 6.5B | 6.9B | 0.5% | 7.4B | 7.5B | 8.0B | 7.2% |
| EPS | 4.19 | 4.22 | 4.44 | 4.59 | 3.1% | 5.07 | 5.09 | 5.55 | 10.0% |
| Shares | 295.0M | 292.1M | 285.2M | 283.1M | -4.0% | 282.0M | — | — | — |
| Debt | 2.8B | 2.7B | 3.4B | 3.4B | 6.6% | 4.1B | — | — | — |
| Equity | 5.3B | 5.8B | 5.9B | 6.7B | 8.3% | — | — | — | — |
| Op CF | 1.3B | 1.8B | 1.8B | 1.6B | 5.9% | 1.6B | — | — | — |
| Inv CF | -338.0M | -310.0M | -1.3B | -394.0M | — | — | — | — | — |
| Fin CF | -1.4B | -930.0M | -752.0M | -715.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of A are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| A | Agilent Technologies, Inc.(you) | $43.4B | 75 | Buy |
| IQV | IQVIA Holdings Inc. | $43.1B | 73 | Buy |
| ILMN | Illumina, Inc. | $32.6B | 75 | Buy |
| WAT | Waters Corporation | $40.7B | 62 | Hold |
| DGX | Quest Diagnostics Incorporated | $26.8B | 82 | Strong Buy |
| IDXX | IDEXX Laboratories, Inc. | $43.7B | 58 | Hold |
| LH | Labcorp Holdings Inc. | $27.2B | 83 | Strong Buy |
| NTRA | Natera, Inc. | $47.0B | 56 | Hold |
| MEDP | Medpace Holdings, Inc. | $16.8B | 80 | Strong Buy |
| RVTY | Revvity, Inc. | $14.4B | 64 | Hold |
Peer medians: ROE -30.7% · P/E 26.9x · Gross margin 58.3%